Cumberland Pharmaceuticals and Pernix Therapeutics will be promoting a novel ulcer treatment in the U.S. under a new agreement. Cumberland, a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products, will promote Omeclamox-Pak® to gastroenterologists across the country through its field sales force, while Pernix, which does the same for branded, generic and OTC pharmaceutical products, will promote the product through its specialty sales force focusing on select primary care physicians. The companies say they will cooperate in the marketing and other activities needed to support the brand’s commercialization.
Omeclamox-Pak combines omeprazole, amoxicillin, and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease. The firms say it is the first FDA-approved triple-combination medication to contain omeprazole as the proton pump inhibitor. The treatment was approved in 2011.
“We have been searching for an FDA-approved gastroenterology product that can be featured by our field sales force,” said A.J. Kazimi, CEO of Cumberland Pharmaceuticals, in a statement. “We look forward to featuring this important product to caregivers and their patients suffering from ulcers caused by H. pylori infections.”
